SCHEMBL6794055

SCHEMBL6794055

O=C1c2cc(O)ccc2CC12Cc1ccccc1C2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 6/20 0.44
ESR2 Q92731 6/20 0.44
PBRM1 Q86U86 1/20 0.44
MAOB P27338 4/20 0.44
MAOA P21397 3/20 0.44
ALDH1A1 P00352 2/20 0.43
MAPT P10636 1/20 0.43
RAB9A P51151 1/20 0.43
LMNA P02545 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA7 P43166 1/20 0.42
CA9 Q16790 1/20 0.42
MAPK14 Q16539 1/20 0.40
AVPR1A P37288 1/20 0.40
CES2 O00748 1/20 0.40
UGT1A1 P22309 1/20 0.38
NTRK1 P04629 1/20 0.38
CCNA2 P20248 1/20 0.38
CDK2 P24941 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6794708 0.91 PBRM1 (0.46) ESR1ESR2PBRM1MAOBMAOA
SCHEMBL6799161 0.87 PBRM1 (0.47) ESR1ESR2PBRM1MAOBMAOA
SCHEMBL6794474 0.86 ESR2 (0.45) ESR1ESR2MAOBMAOAALDH1A1
SCHEMBL1463836 0.83 TDP1 (0.56) CA1CA2CA7CA9AVPR1A
SCHEMBL29620731 0.83 TDP1 (0.56) CA1CA2CA7CA9AVPR1A
SCHEMBL6806691 0.81 ESR2 (0.46) ESR1ESR2PBRM1MAOBMAOA
SCHEMBL17355137 0.79 L3MBTL1 (0.36) MAOAALDH1A1LMNA
SCHEMBL6800174 0.79 PBRM1 (0.49) ESR1ESR2PBRM1MAOBMAOA
SCHEMBL17355128 0.79 ESR1 (0.42) ESR1ESR2PBRM1MAOBMAOA
SCHEMBL27453676 0.79 PBRM1 (0.41) ESR1ESR2PBRM1MAOBMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040082642-A1 Novel estrogen receptor ligands and method III MERCK & CO., INC. 2004-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082642-A1 Novel estrogen receptor ligands and method III ESRRA, ESRRB, FSHR ESR1 19/4885ESR2 5/4885PBRM1 4775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.